Circio Holding ASA

Circio Holding ASA in the news! An article on Circio’s Vision For Long-Lasting Nucleic Acid Therapeutics published in InVivo.

A recording of our R&D and corporate update webcast from today is now available on the Circio webpage.

Circio announces novel circVec 3.0 generation and circular mRNA half-life up to 75 times longer than linear mRNA in vivo ·      Novel circVec 3.0 design feature achieves 27- and 4-fold improvement vs. circVec 1.1 and 2.1 generation, respectively ·      circVec circular mRNA shows up to 75 times longer half-life than conventional linear mRNA in vivo ·      Muscle-specific circVec 2.0-AAV vectors validated by systemic delivery in vivo ·      The results will be discussed in a live webcast at 10am CEST on 4 December 2024   

Circio Holding ASA invites to R&D and corporate update webcast on 4 December 2024 Circio invites to a live webcast at 10:00am CEST on Wednesday 4 December 2024. In the webcast, Circio management will provide a corporate update and showcase the latest developments for the circVec platform technology.   Presenters: CEO Dr. Erik Digman Wiklund  CTO Dr. Thomas Birkballe Hansen Questions can be submitted in advance by email to: erik.wiklund@circio.com or directly in the live webcast. A recording of the webcast will be made available on the Circio webpage. Time: 10:00 CEST on 4 December 2024 Click here to access Teams webcast: Meeting ID: 349 042 796 001 Passcode: 2PM24NF6

Circio is teaming up with the LNP-experts at Certest for delivery of our circVec-DNA gene therapy format to specific tissues. circVec-DNA has already demonstrated remarkable >6 months durability on a single dose and uo to 15x improvement vs. standard mRNA-based vector systems in muscle tissue. The Certest collaboration will enable us to extend these promising results to other tissues to identify target diseases for development of novel circVec therapeutic candidates.

Circio announces circVec LNP-delivery collaboration with Certest progressing to in vivo testing

Circio's CFO Lubor Gaal shares his perspectives on current biopharma deal-making with an industry veteran panel at BioEurope in Stockholm today

Circio presents circVec circular RNA in vivo expression proof-of-concept data at ESGCT 2024 annual meeting Circio selected to present its circVec circular RNA expression platform at the European Society of Gene and Cell Therapy (ESGCT) annual meeting in Rome 22-25 October: ·     Circio presented new circVec protein expression data showing statistically significant advantage vs. conventional mRNA-based vector expression both in vitro and in vivo ·     The circVec 2.1 generation shows 15x increase in protein expression in vivo, and has the potential to substantially improve on the performance of current gold-standard gene therapy approaches

Circio has been selected to present its circVec circular RNA expression platform at the European Society of Cell and Gene Therapy (ESGCT) annual meeting 2024!

Pivoting To RNA With Erik Digman Wiklund Listen to this episode of the Business of Biotech podcast here: